Search

Your search keyword '"Stebbing, Justin"' showing total 2,058 results
Start Over Author "Stebbing, Justin"
2,058 results on '"Stebbing, Justin"'

1. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

Author

Bullock, Andrea J., Schlechter, Benjamin L., Fakih, Marwan G., Tsimberidou, Apostolia M., Grossman, Joseph E., Gordon, Michael S., Wilky, Breelyn A., Pimentel, Agustin, Mahadevan, Daruka, Balmanoukian, Ani S., Sanborn, Rachel E., Schwartz, Gary K., Abou-Alfa, Ghassan K., Segal, Neil H., Bockorny, Bruno, Moser, Justin C., Sharma, Sunil, Patel, Jaymin M., Wu, Wei, Chand, Dhan, Rosenthal, Katherine, Mednick, Gabriel, Delepine, Chloe, Curiel, Tyler J., Stebbing, Justin, Lenz, Heinz-Josef, O’Day, Steven J., and El-Khoueiry, Anthony B.

Published
2024
Full Text
View/download PDF

4. The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS

Author

Grigoropoulos, Ioannis, Tsioulos, Georgios, Kastrissianakis, Artemis, Shapira, Shiran, Green, Orr, Rapti, Vasiliki, Tsakona, Maria, Konstantinos, Thomas, Savva, Athina, Kavatha, Dimitra, Boumpas, Dimitrios, Syrigos, Konstantinos, Xynogalas, Ioannis, Leontis, Konstantinos, Ntousopoulos, Vasileios, Sakka, Vissaria, Sardelis, Zafeiris, Fotiadis, Andreas, Vlassi, Lamprini, Kontogianni, Chrysoula, Levounets, Anastasia, Poulakou, Garyfalia, Gaga, Mina, MacLoughlin, Ronan, Stebbing, Justin, Arber, Nadir, Antoniadou, Anastasia, and Tsiodras, Sotirios

Published
2024
Full Text
View/download PDF

5. A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome

Author

Hammond, Terese C., Purbhoo, Marco A., Kadel, Sapana, Ritz, Jerome, Nikiforow, Sarah, Daley, Heather, Shaw, Kit, van Besien, Koen, Gomez-Arteaga, Alexandra, Stevens, Don, Ortuzar, Waldo, Michelet, Xavier, Smith, Rachel, Moskowitz, Darrian, Masakayan, Reed, Yigit, Burcu, Boi, Shannon, Soh, Kah Teong, Chamberland, John, Song, Xin, Qin, Yu, Mishchenko, Ilya, Kirby, Maurice, Nasonenko, Valeriia, Buffa, Alexa, Buell, Jennifer S., Chand, Dhan, van Dijk, Marc, Stebbing, Justin, and Exley, Mark A.

Published
2024
Full Text
View/download PDF

7. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.

Author

Glaviano, Antonino, Foo, Aaron, Lam, Hiu, Yap, Kenneth, Jacot, William, Jones, Robert, Eng, Huiyan, Nair, Madhumathy, Makvandi, Pooyan, Geoerger, Birgit, Kulke, Matthew, Baird, Richard, Prabhu, Jyothi, Carbone, Daniela, Pecoraro, Camilla, Teh, Daniel, Sethi, Gautam, Cavalieri, Vincenzo, Lin, Kevin, Javidi-Sharifi, Nathalie, Toska, Eneda, Davids, Matthew, Brown, Jennifer, Diana, Patrizia, Stebbing, Justin, Kumar, Alan, and Fruman, David

Subjects
AKT inhibitors, ATP-competitive mTOR inhibitors, Allosteric mTOR inhibitors, Bi-steric mTOR inhibitors, Cancer, Dual PI3K/mTOR inhibitors, Isoform-specific PI3K inhibitors, PDK1 inhibitors, PI3K/AKT/mTORC pathway, Pan PI3K inhibitors, Humans, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Signal Transduction, TOR Serine-Threonine Kinases, Neoplasms
Abstract

The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth factor signalling to transcription factors in the PAM axis is highly regulated by multiple cross-interactions with several other signaling pathways, and dysregulation of signal transduction can predispose to cancer development. The PAM axis is the most frequently activated signaling pathway in human cancer and is often implicated in resistance to anticancer therapies. Dysfunction of components of this pathway such as hyperactivity of PI3K, loss of function of PTEN, and gain-of-function of AKT, are notorious drivers of treatment resistance and disease progression in cancer. In this review we highlight the major dysregulations in the PAM signaling pathway in cancer, and discuss the results of PI3K, AKT and mTOR inhibitors as monotherapy and in co-administation with other antineoplastic agents in clinical trials as a strategy for overcoming treatment resistance. Finally, the major mechanisms of resistance to PAM signaling targeted therapies, including PAM signaling in immunology and immunotherapies are also discussed.

Published
2023

9. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment

Author

Glaviano, Antonino, Wander, Seth A., Baird, Richard D., Yap, Kenneth C.-H., Lam, Hiu Yan, Toi, Masakazu, Carbone, Daniela, Geoerger, Birgit, Serra, Violeta, Jones, Robert H., Ngeow, Joanne, Toska, Eneda, Stebbing, Justin, Crasta, Karen, Finn, Richard S., Diana, Patrizia, Vuina, Karla, de Bruin, Robertus A.M., Surana, Uttam, Bardia, Aditya, and Kumar, Alan Prem

Published
2024
Full Text
View/download PDF

10. Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer

Author

Shaw, Jacqueline A., Page, Karen, Wren, Evie, de Bruin, Elza C., Kalashnikova, Ekaterina, Hastings, Robert, McEwen, Rob, Zhang, Eddie, Wadsley, Marc, Acheampong, Emmanuel, Renner, Derrick, Gleason, Kelly L.T., Ambasager, Bana, Stetson, Daniel, Fernandez-Garcia, Daniel, Guttery, David, Allsopp, Rebecca C., Rodriguez, Angel, Zimmermann, Bernhard, Sethi, Himanshu, Aleshin, Alexey, Liu, Minetta C., Richards, Cathy, Stebbing, Justin, Ali, Simak, Rehman, Farah, Cleator, Susan, Kenny, Laura, Ahmed, Samreen, Armstrong, Anne C., and Coombes, R. Charles

Published
2024
Full Text
View/download PDF

11. Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial

Author

Stebbing, Justin, Baranau, Yauheni, Baryash, Valery, Moiseyenko, Vladimir, Boliukh, Dmytro, Antone, Nicoleta, Manikhas, Alexey, Chornobai, Anatolii, Park, Taehong, Baek, Eric Hyungseok, Lee, Jaeyong, Choi, Jiin, Kim, Nahyun, Ahn, Keumyoung, Lee, Sang Joon, and Kim, Sunghyun

Published
2023
Full Text
View/download PDF

12. A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease

Author

Mato Prado, Mireia, Puik, Jisce R., Castellano, Leandro, López-Jiménez, Elena, Liu, Daniel S. K., Meijer, Laura L., Le Large, Tessa Y. S., Rees, Eleanor, Funel, Niccola, Sivakumar, Shivan, Pereira, Stephen P., Kazemier, Geert, Zonderhuis, Babs M., Erdmann, Joris I., Swijnenburg, Rutger-Jan, Frilling, Andrea, Jiao, Long R., Stebbing, Justin, Giovannetti, Elisa, Krell, Jonathan, and Frampton, Adam E.

Published
2023
Full Text
View/download PDF

15. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

Author

Magbanua, Mark Jesus M, Hendrix, Laura H, Hyslop, Terry, Barry, William T, Winer, Eric P, Hudis, Clifford, Toppmeyer, Deborah, Carey, Lisa Anne, Partridge, Ann H, Pierga, Jean-Yves, Fehm, Tanja, Vidal-Martínez, José, Mavroudis, Dimitrios, Garcia-Saenz, Jose A, Stebbing, Justin, Gazzaniga, Paola, Manso, Luis, Zamarchi, Rita, Antelo, María Luisa, De Mattos-Arruda, Leticia, Generali, Daniele, Caldas, Carlos, Munzone, Elisabetta, Dirix, Luc, Delson, Amy L, Burstein, Harold J, Qadir, Misbah, Ma, Cynthia, Scott, Janet H, Bidard, François-Clément, Park, John W, and Rugo, Hope S

Subjects
Cancer, Prevention, Breast Cancer, Clinical Research, Breast Neoplasms, Female, Humans, Neoplastic Cells, Circulating, Prognosis, Progression-Free Survival, Proportional Hazards Models, Reproducibility of Results, Retrospective Studies, Treatment Outcome, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundWe examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy.MethodsSerial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS.ResultsLatent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P < .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model.ConclusionsWe identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.

Published
2021

20. Resveratrol and Female Fertility: A Systematic Review.

Author

Bertoldo, Alessandro, Pizzol, Damiano, Yon, Dong Keon, Callegari, Maura, Gobbo, Valentina, Cuccurese, Pierluigi, Butler, Laurie, Caminada, Susanna, Stebbing, Justin, Richardson, Fiona, Gawronska, Julia, and Smith, Lee

Abstract

Resveratrol is a natural polyphenolic compound that may have multiple influences on human health, including antiaging, anti-inflammatory, anti-neoplastic, antioxidant, insulin-sensitizing, cardioprotective and vasodilating activities. Growing evidence also suggests a potential positive effect of resveratrol on female fertility. The aim of the present study was to collate and appraise the scientific literature on the relationship between resveratrol and female fertility. We systematically searched Medline, PubMed, Web of Science and Embase from the databases' inception (1951, 1951, 1947 and 1900, respectively) until 9th May 2024. All in vivo or in vitro retrospective or prospective studies reporting the effects of resveratrol interventions on women's fertility were included. We ultimately incorporated twenty-four studies into a systematic review with a narrative summary of the results; of those studies, nine were performed on women seeking natural or assisted fertility, and fifteen were in vitro studies performed on human cells and tissues in different stages of the reproductive cascade. The current literature, though limited, suggests that resveratrol may play a role in female infertility. Specifically, it may significantly and positively impact reproductive outcomes, owing to its potential therapeutic effects improving ovarian function. Further studies are now needed to better understand resveratrol's effects and define the optimal dosage and periods of intake to maximize beneficial effects, as well as to prevent adverse outcomes on implantation, subsequent pregnancy and the fetus. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients

Author

Nteliopoulos, Georgios, Page, Karen, Hills, Allison, Howarth, Karen, Emmett, Warren, Green, Emma, Martinson, Luke J., Fernadez-Garcia, Daniel, Hastings, Robert, Guttery, David S., Kenny, Laura, Stebbing, Justin, Cleator, Susan, Rehman, Farah, Gleason, Kelly L. T., Sanela, Andrijac, Ion, Charlotte, Rushton, Amelia J., Rosenfeld, Nitzan, Coombes, R. Charles, and Shaw, Jacqueline A.

Published
2021
Full Text
View/download PDF

34. Kinome‐Wide Synthetic Lethal Screen Identifies PANK4 as a Modulator of Temozolomide Resistance in Glioblastoma

Author

Vella, Viviana, primary, Ditsiou, Angeliki, additional, Chalari, Anna, additional, Eravci, Murat, additional, Wooller, Sarah K., additional, Gagliano, Teresa, additional, Bani, Cecilia, additional, Kerschbamer, Emanuela, additional, Karakostas, Christos, additional, Xu, Bin, additional, Zhang, Yongchang, additional, Pearl, Frances M.G., additional, Lopez, Gianluca, additional, Peng, Ling, additional, Stebbing, Justin, additional, Klinakis, Apostolos, additional, and Giamas, Georgios, additional

Published
2024
Full Text
View/download PDF

35. PIK3C[delta] expression by fibroblasts promotes triple-negative breast cancer progression

Author

Gagliano, Teresa, Shah, Kalpit, Gargani, Sofia, Lao, Liyan, Alsaleem, Mansour, Chen, Jianing, Ntafis, Vasileios, Huang, Penghan, Ditsiou, Angeliki, Vella, Viviana, Yadav, Kritika, Bienkowska, Kamila, Bresciani, Giulia, Kang, Kai, Li, Leping, Carter, Philip, Benstead-Hume, Graeme, OHanlon, Timothy, Dean, Michael, Pearl, Frances M.G., Lee, Soo-Chin, Rakha, Emad A., Green, Andrew R., Kontoyiannis, Dimitris L., Song, Erwei, Stebbing, Justin, and Giamas, Georgios

Subjects
Genetic engineering -- Analysis, Idelalisib -- Analysis, Breast cancer -- Development and progression, Cancer metastasis -- Development and progression, RNA -- Analysis, Health care industry
Abstract

As there is growing evidence for the tumor microenvironment's role in tumorigenesis, we investigated the role of fibroblast-expressed kinases in triple-negative breast cancer (TNBC). Using a high-throughput kinome screen combined with 3D invasion assays, we identified fibroblast-expressed PIK3C[delta] (f- PIK3C[delta]) as a key regulator of cancer progression. Although PIK3C[delta] was expressed in primary fibroblasts derived from TNBC patients, it was barely detectable in breast cancer (BC) cell lines. Genetic and pharmacological gain- and loss-of-function experiments verified the contribution of f-PIK3C[delta] in TNBC cell invasion. Integrated secretomics and transcriptomics analyses revealed a paracrine mechanism via which f-PIK3C[delta] confers its protumorigenic effects. Inhibition of f-PIK3C[delta] promoted the secretion of factors, including PLGF and BDNF, that led to upregulation of NR4A1 in TNBC cells, where it acts as a tumor suppressor. Inhibition of PIK3C[delta] in an orthotopic BC mouse model reduced tumor growth only after inoculation with fibroblasts, indicating a role of f-PIK3C[delta] in cancer progression. Similar results were observed in the MMTV-PyMT transgenic BC mouse model, along with a decrease in tumor metastasis, emphasizing the potential immune-independent effects of PIK3C[delta] inhibition. Finally, analysis of BC patient cohorts and TCGA data sets identified f-PIK3C[delta] (protein and mRNA levels) as an independent prognostic factor for overall and disease-free survival, highlighting it as a therapeutic target for TNBC., Introduction Triple-negative breast cancer (TNBC; [ER.sup.-], [PR.sup.-], [HER2.sup.-]) represents a molecularly diverse and highly heterogeneous subtype of breast cancer (BC) (15%-20%) with a poor prognosis and high rates of recurrence [...]

Published
2020
Full Text
View/download PDF

36. Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation

Author

Jin, Ying, Bao, Hua, Le, Xiuning, Fan, Xiaojun, Tang, Ming, Shi, Xun, Zhao, Jun, Yan, Junrong, Xu, Yang, Quek, Kelly, Elamin, Yasir Y., Zhang, Jianhua, Futreal, P. Andrew, Wistuba, Ignacio I., Heymach, John V., Lou, Guangyuan, Shao, Lan, He, Qiong, Lin, Chen, Wu, Xue, Shao, Yang W., Wang, Xiaonan, He, Jiachen, Chen, Yamei, Stebbing, Justin, Chen, Ming, Zhang, Jianjun, and Yu, Xinmin

Published
2020
Full Text
View/download PDF

39. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

Author

Cristofanilli, Massimo, Pierga, Jean-Yves, Reuben, James, Rademaker, Alfred, Davis, Andrew A., Peeters, Dieter J., Fehm, Tanja, Nolé, Franco, Gisbert-Criado, Rafael, Mavroudis, Dimitrios, Grisanti, Salvatore, Giuliano, Mario, Garcia-Saenz, Jose A., Stebbing, Justin, Caldas, Carlos, Gazzaniga, Paola, Manso, Luis, Zamarchi, Rita, de Lascoiti, Angela Fernandez, De Mattos-Arruda, Leticia, Ignatiadis, Michail, Cabel, Luc, van Laere, Steven J., Meier-Stiegen, Franziska, Sandri, Maria-Teresa, Vidal-Martinez, Jose, Politaki, Eleni, Consoli, Francesca, Generali, Daniele, Cappelletti, Maria Rosa, Diaz-Rubio, Eduardo, Krell, Jonathan, Dawson, Sarah-Jane, Raimondi, Cristina, Rutten, Annemie, Janni, Wolfgang, Munzone, Elisabetta, Carañana, Vicente, Agelaki, Sofia, Almici, Camillo, Dirix, Luc, Solomayer, Erich-Franz, Zorzino, Laura, Darrigues, Lauren, Reis-Filho, Jorge S., Gerratana, Lorenzo, Michiels, Stefan, Bidard, François-Clément, and Pantel, Klaus

Published
2019
Full Text
View/download PDF

41. LMTK3 gene expression and the molecular landscape of colorectal cancer (CRC).

Author

Torres-Gonzalez, Lesly, primary, Battaglin, Francesca, additional, Soni, Shivani, additional, Baca, Yasmine, additional, Xiu, Joanne, additional, Walker, Phillip, additional, Lo, Jae Ho, additional, Algaze, Sandra, additional, Jayachandran, Priya, additional, Mittal, Pooja, additional, Zhang, Wu, additional, Weinberg, Benjamin Adam, additional, Lou, Emil, additional, Shields, Anthony F., additional, Goldberg, Richard M., additional, Marshall, John, additional, Goel, Sanjay, additional, Stebbing, Justin, additional, Giamas, Georgios, additional, and Lenz, Heinz-Josef, additional

Published
2024
Full Text
View/download PDF

49. The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention

Author

Renziehausen, Alexander, Wang, Hexiao, Rao, Bhavya, Weir, Lynda, Nigro, Cristiana Lo, Lattanzio, Laura, Merlano, Marco, Vega-Rioja, Antonio, del Carmen Fernandez-Carranco, Maria, Hajji, Nabil, Matin, Rubeta, Harwood, Catherine, Li, Su, Sim, Van Ren, O’Neill, Kevin, Evans, Alan, Thompson, Alastair, Szlosarek, Peter, Fleming, Colin, Stebbing, Justin, Proby, Charlotte, Tzakos, Andreas G., Syed, Nelofer, and Crook, Tim

Published
2019
Full Text
View/download PDF

50. Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation

Author

Li, Jisheng, Zhu, Liping, Stebbing, Justin, and Peng, Ling

Subjects
Gene mutations -- Case studies, Lung cancer, Non-small cell -- Genetic aspects -- Drug therapy -- Case studies, Health
Abstract

Byline: Jisheng. Li, Liping. Zhu, Justin. Stebbing, Ling. Peng Classical activating alterations including exon 19 deletions and exon 21 L858R point mutations comprise the majority of epidermal growth factor receptor [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results